

Non-consolidated Financial Results
for the Nine Months Ended September 30, 2025
[Under Japanese GAAP]

Company name: Veritas In Silico Inc.
Listing: Tokyo Stock Exchange
Securities code: 130A
URL: <https://www.veritasinsilico.com/en/>
Representative: Shingo NAKAMURA, Representative Director and CEO
Inquiries: Tsuneo GODA, Executive Officer and General Manager of Corporate Planning Division
Telephone: +81-3-6421-7537
Scheduled date to commence dividend payments: None
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Non-consolidated Financial Results for the Nine Months Ended September 30, 2025 (from January 1, 2025 to September 30, 2025)

(1) Non-consolidated Business Results (cumulative)

(Percentages indicate year-on-year changes.)

	Business revenue		Operating profit		Ordinary profit		Net profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended								
September 30, 2025	65	(60.1)	(287)	-	(283)	-	(285)	-
September 30, 2024	165	(40.9)	(121)	-	(143)	-	(145)	-

	Earnings per share	Diluted earnings per share
	Yen	Yen
Nine months ended		
September 30, 2025	(44.00)	-
September 30, 2024	(23.00)	-

Notes: Diluted earnings per share are not shown in the above table, because, although there are residual shares, earnings per share were ultimately negative.

(2) Non-consolidated Financial Position

	Total assets	Net assets	Equity ratio
	Millions of yen	Millions of yen	%
As of			
September 30, 2025	1,984	1,924	96.9
December 31, 2024	2,248	2,209	98.2

Reference: Equity

As of September 30, 2025: 1,924 Million Yen

As of December 31, 2024: 2,209 Million Yen

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

2. Cash dividends

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2024	-	0.00	-	0.00	0.00
Fiscal year ending December 31, 2025	-	0.00	-		
Fiscal year ending December 31, 2025 (Forecast)			-	0.00	0.00

Note: Revisions to the most recently announced forecasts: None

3. Forecasts for the Fiscal Year Ending December 31, 2025

(Percentages indicate year-on-year changes.)

	Business revenue		Operating profit		Ordinary profit		Net profit		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending December 31, 2025	91	(53.2)	(397)	-	(391)	-	(394)	-	(60.77)

Notes: Revisions to the most recently announced forecasts: None

* Notes

- (1) Adoption of accounting treatment specific to the preparation of quarterly non-consolidated financial statements: None
- (2) Changes in accounting policies, changes in accounting estimates, and restatement
 - (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
 - (ii) Changes in accounting policies due to other reasons: None
 - (iii) Changes in accounting estimates: None
 - (iv) Restatement: None
- (3) Number of issued shares (common shares)

- (i) Total number of issued shares at the end of the period (including treasury shares)

As of September 30, 2025	6,487,114 shares
Fiscal year ended December 31, 2024	6,487,114 shares

- (ii) Number of treasury shares at the end of the period

As of September 30, 2025	- shares
Fiscal year ended December 31, 2024	- shares

- (iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Nine months ended September 30, 2025	6,487,114 shares
Nine months ended September 30, 2024	6,332,055 shares

* Review of the Japanese-language originals of the quarterly non-consolidated financial statements by certified public accountant or audit firm: Yes (voluntarily attached only to the Japanese original)

* Proper use of earnings forecasts, and other remarks

(Disclaimer Regarding Forward-Looking Statements, etc.)

The forecasts and other forward-looking statements contained in this document are based on information available to the Company at the time this document was released and on certain assumptions that the Company has regarded as reasonable.

Please refer to “1. Qualitative Information on Financial Results (3) Financial Forecasts and Other Forward-Looking Statements” on page 3 of the attached materials for matters related to earnings forecasts.

○Table of Contents for Appendix

1. Qualitative Information on Financial Results	2
(1) Explanation on Business Results	2
(2) Explanation on Financial Position	2
(3) Financial Forecasts and Other Forward-Looking Statements	3
2. Quarterly Non-consolidated Financial Statements and Major Notes	4
(1) Quarterly Balance Sheet	4
(2) Quarterly Profit and Loss	6
(3) Notes to Quarterly Financial Statements	7
(Notes on going concern assumption)	7
(Notes in the case of significant changes in shareholders' equity).....	7
(Segment information, etc.).....	7
(Notes on cash flow statements)	7
(Significant subsequent events)	7

1. Qualitative Information on Financial Results

(1) Explanation on Business Results

During the third quarter of the fiscal year ending December 31, 2025 under review (January 1, 2025 - September 30, 2025), The global economy demonstrated resilience in the face of uncertainty surrounding future trade policies, particularly those initiated by the U.S. government. In Japan, the inflation rate decelerated, real wages exhibited an annual increase, and corporate capital investment demonstrated a strong inclination to enhance supply chains and pursue digital transformation. Indicators of business sentiment are showing signs of improvement.

In the mRNA-targeted small molecule drug discovery business, the Company is conducting joint drug discovery research with Toray Industries, Inc., Shionogi & Co., Ltd., RaQualia Pharma Inc., and Takeda Pharmaceutical Company Limited, utilizing its drug discovery platform, ibVIS[®]. To secure additional partners, the Company has approached domestic and international pharmaceutical companies interested in mRNA-targeted small molecule drug discovery, introducing the platform technology. Additionally, the Company has obtained Patent Rights in the European region in January and in the United States in July for its foundational technology for RNA-targeted small molecule drug discovery—the core of the ibVIS[®] drug discovery platform—achieving patent protection in Japan, Europe, and the United States.

In the pipeline business, where the Company has been advancing efforts to diversify its revenue base, the Company has narrowed down candidates from thousands of genes based on selection criteria such as high anticipated future value and relatively short, expected R&D periods to market launch. The Company has defined the first modality in its proprietary pipeline as a nucleic acid-based drug targeting ischemic acute renal failure induced after cardiovascular surgery and has commenced its proprietary drug discovery research. In June, the Company entered into a joint research agreement with Mitsubishi Gas Chemical Company, Inc. The objective of the agreement is to establish research, development, and manufacturing technologies for ASOs. In addition, in September, the Company initiated a joint research project with Jikei University School of Medicine. A primary objective of the collaboration is to demonstrate novel therapeutic methods and drug delivery approaches that maximize primary effects while minimizing side effects by efficiently delivering pharmaceuticals to target organs. This approach also seeks to reduce dosage while maintaining high therapeutic efficacy.

During the third quarter of the current fiscal year, joint drug discovery research for mRNA-targeted small molecule drugs with each partner progressed as planned. In May, the company achieved a significant milestone in its joint research with Shionogi & Co., Inc. by successfully acquiring compounds that led to the identification of a lead compound. Furthermore, the scope of research on the target genes covered by the joint research was expanded in its joint research with RaQualia Pharma Inc., which aimed at creating cancer therapeutics. By leveraging the expertise of both parties, we were able to conduct multiple screenings against multiple genes. This resulted in the acquisition of several low-molecular-weight compounds that have the potential to serve as starting points for drug discovery research.

The Company's Business revenue in the period totaled 65,920 thousand yen (down 60.1% year-on-year) from research support funds received periodically under collaborative research agreements and spot milestone payments. Business expenses totaled 353,710 thousand yen, including R&D expenses of 153,707 thousand yen, resulting in an Operating loss of 287,790 thousand yen (Operating loss of 121,716 thousand yen in the same quarter of the previous year). Non-operating income totaled 4,720 thousand yen, including an interest income of 4,424 thousand yen, resulting in an Ordinary loss of 283,070 thousand yen (Ordinary loss of 143,472 thousand yen in the same quarter of the previous year) and Net loss for the period of 285,454 thousand yen (Net loss of 145,609 thousand yen in the same quarter of the previous year).

(2) Explanation of Financial Position

(Assets)

Total assets at the end of the third quarter of the current fiscal year decreased by 264,135 thousand yen (11.7%) compared to the end of the previous fiscal year to 1,984,823 thousand yen. Current assets decreased by 296,486 thousand yen (13.3%) to 1,935,586 thousand yen, primarily due to a decrease of 400,000 thousand yen in term deposits included in cash and deposits, an increase of ¥128,899 thousand in ordinary deposits, and a decrease of ¥21,019 thousand in accounts receivable. Non-current assets increased by 32,351 thousand yen (191.6%), reaching 49,236 thousand yen, mainly due to an increase in Property, plant and equipment of 11,443 thousand yen (resulting from the acquisition of tangible Fixed assets and a decrease of 9,359 thousand yen due to Depreciation) and an increase in security deposits included in Investments and other assets of 17,637 thousand yen.

(Liabilities)

Liabilities at the end of the third quarter of the current fiscal year increased by 21,319 thousand yen (54.1%) compared to the end of the previous fiscal year to 60,729 thousand yen. It is mainly due to an increase of 13,566 thousand yen in Accounts payable and an increase in 5,500 thousand yen in Advances received in Current liabilities.

(Net assets)

Net assets at the end of the third quarter of the current fiscal year decreased by 285,454 thousand yen (12.9%) compared to the end of the previous fiscal year to 1,924,093 thousand yen. This was due to a decrease of 285,454 thousand yen in Retained earnings.

As a result of these factors, the equity ratio decreased by 1.3 points from 98.2% at the end of the previous fiscal year to 96.9%.

(3) Financial Forecasts and Other Forward-Looking Statements

Based on current performance trends and others, the Company revised its annual earnings forecast for the FY2025 on October 14, 2025. For details, please refer to the Company's timely disclosure release dated October 14, 2025, titled "Revised Financial Forecast for FY2025."

As of the date of this document, the U.S. government's tariff measures have not had any particular impact on the Company's Business activities, Operating results, or Financial condition.

The forecasts and other forward-looking statements in this document are based on certain assumptions that the Company considers reasonable, using information available as of the date of this document. Please note that actual performance may differ significantly from these forecasts and statements due to various factors that may arise in the future.

2. Quarterly Non-consolidated Financial Statements and Major Notes

(1) Quarterly Balance Sheet

(Thousands of yen)

	As of December 31, 2024	As of September 30, 2025
Assets		
Current assets		
Cash and deposits	2,173,358	1,902,258
Accounts receivable - trade	21,019	-
Supplies	13,350	11,696
Advance payments to suppliers	2,875	5,722
Prepaid expenses	1,662	2,494
Others	19,806	13,413
Total current assets	2,232,073	1,935,586
Non-current assets		
Property, plant and equipment	14,115	25,558
Intangible assets		
Software	325	468
Patent right	758	3,711
Total intangible assets	1,084	4,180
Investments and other assets	1,685	19,497
Total non-current assets	16,885	49,236
Total assets	2,248,958	1,984,823

(Thousands of yen)

	As of December 31, 2024	As of September 30, 2025
Liabilities		
Current liabilities		
Accounts payable	33,664	47,231
Income taxes payable	2,850	2,137
Advances received	-	5,500
Others	2,895	5,860
Total current liabilities	39,410	60,729
Total liabilities	39,410	60,729
Net assets		
Shareholders' equity		
Share capital	77,175	10,000
Capital surplus	2,335,766	2,402,941
Retained earnings	(203,393)	(488,848)
Total shareholders' equity	2,209,548	1,924,093
Total net assets	2,209,548	1,924,093
Total liabilities and net assets	2,248,958	1,984,823

(2) Quarterly Profit and Loss Cumulative Period for the Third Quarter

(Thousands of yen)

	For the nine months ended September 30, 2024	For the nine months ended September 30, 2025
Business revenue	165,134	65,920
Business expenses		
Research and development expenses	117,274	153,707
Selling, general and administrative expenses	169,576	200,002
Total business expenses	286,850	353,710
Operating loss	(121,716)	(287,790)
Non-operating income		
Interest income	194	4,424
Lecture fee	223	175
Others	3	119
Total non-operating income	420	4,720
Non-operating expenses		
Listing expenses	12,820	-
Share issuance costs	9,351	-
Others	5	-
Total non-operating expenses	22,176	-
Ordinary loss	(143,472)	(283,070)
Loss before income taxes	(143,472)	(283,070)
Income taxes - current	2,137	2,384
Total income taxes	2,137	2,384
Loss	(145,609)	(285,454)

(3) Notes to Quarterly Financial Statements

(Notes on going concern assumption)

Not applicable

(Notes in the case of significant changes in shareholders' equity)

Based on the resolution of the regular shareholders' meeting held on March 27, 2025, the Company's capital reduction took effect on May 1, 2025, and the capital stock of 67,175 thousand yen was transferred to other capital surplus.

As a result, at the end of the third quarter cumulative period, the capital stock is 10,000 thousand yen and the capital surplus is 2,402,941 thousand yen.

(Additional information)

(Impact of changes in corporate income tax and other related tax rates)

Following the enactment of the Act Partially Amending the Income Tax Act, etc. (Act No. 13 of 2025) by the National Diet on March 31, 2025, a Defense Special Corporate Tax will be imposed starting from fiscal years beginning on or after April 1, 2026. In line with this change, for deferred tax assets and deferred tax liabilities associated with temporary differences expected to be resolved in fiscal years beginning on or after January 1, 2027, we have revised the statutory effective tax rate from 34.59% to 35.43% for calculation purposes. The impact of this tax rate change is immaterial.

(Segment information, etc.)

Segment information is omitted as the Company operates in a single business segment of the drug discovery platform business.

(Notes on cash flow statements)

The Company has not prepared the quarterly cash flow statement for the third quarter of the current fiscal year. The depreciation expenses, including amortization expenses for Intangible assets, for the third quarter of the current and previous fiscal year are as follows.

	Nine months ended September 30, 2024	Nine months ended September 30, 2025
Depreciation expenses	Thousands of Yen 11,369	Thousands of Yen 9,733